COMPANY STATUS

ActiveO has made continuous progress in product development and initial clinical evaluations outside of the United States. The company has moved into a more active clinical and regulatory phase in the United States and Europe based on the success of our work over the past four years. Highlights of the company’s status in terms of milestones, intellectual property, clinical and regulatory pathway, and potential reimbursement are shown below.

Major Milestones

• 2004 November • 2004 December • 2005 July • 2005 November • 2007 January • 2007 June • 2007 December • 2009 March

ActiveO incorporated as an LLC and is funded by the managing partners Development of first-generation product begins Development of second-generation product begins 50 patient clinical trial completed in Europe ActiveO cleanroom and research facility opens in Salt Lake City, Utah (USA) Clinical protocol and animal studies completed Application for 510k clinical trial submitted to United States Food and Drug Administration (FDA) for review Series B capital round opens

The ActiveO AO-1000 device

Product

The initial product under development is the ActiveO AO-1000 device. This device is in the development phase and is not cleared for use in the United States by the FDA.

Intellectual Property

ActiveO has a strong intellectual property portfolio. Nine U.S. patent applications have been filed covering our AO-1000 device and treatment method. We have also filed for patent protection in Europe, Japan, and Australia.

Clinical & Regulatory

ActiveO and their regulatory staff are in regular communication with the FDA. The company announces regular clinical and regulatory milestones to investors and interested parties. To be included in this list, go to more information and provide your contact information.

Return to Top

Copyright © 2009. All rights reserved. I Privacy Policy